News

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

Elevated HDL-C raised glaucoma risk, particularly for participants aged ≥55 years, contrary to its typical beneficial role in cardiovascular health.

This Month in Review highlights the top psychiatry news in January.

Laique reviews data supporting the use of metabolic surgery in patients with obesity and cirrhotic MASH.

The trend warrants attention, given treatment difficulties and the association with other substance use issues, says lead author of Rutgers Health study.

A new tool may enable earlier identification of heart failure, potentially reducing hospitalizations and premature death.

New research tested how specialized hypertennsion medical curriculum impacted residents’ treatment of hypertensive urgency in the outpatient setting.

In a Q&A, Kasia Lipska, MD, MHS, discusses the impact of type 2 diabetes on the immune system and findings from her recent research.

Most deprescribing interventions consist of a clinician being alerted to a potential problem with the patient’s medication but does not provide guidance to the clinician about how to communicate with the patient.

A survey suggests ablation leads to improved sports performance in athletes with atrial fibrillation.

A new app being developed, JomCare, will ask study participants twice a day about their substance cravings and their intention to engage in drug use.

In this quiz, readers will be asked about the pivotal data used to support the July 2024 approval of deuruxolitinib for alopecia areata.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

Laique emphasizes the unmet needs for patients with cirrhotic MASH who are not eligible for resmetirom and what role metabolic surgery may play in their care.

The FDA’s approval marks the second indication for Genentech's refillable ocular implant in addition to wet age-related macular degeneration.

This pulmonology month in review highlights recent research on diagnosing asthma and new pivotal trial data.

These new data were announced by LEO Pharma following the phase 3 DELTA TEEN trial, assessing delgocitinib 20mg/g cream for chronic hand eczema (CHE).

The January 2025 endocrinology month in review highlights the latest from the FDA, key drug price negotiations, and the latest updates to the obesity pipeline.

In this segment of January's Lungcast episode, guests discussed the Global Lung Function Initiative (GLI) network, lung function testing, and the use of race-based normal values.

A list of 10 facts to know about the current landscape of cancer management and oncology research in the US.

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

The month in review spotlights the top news and research in nephrology from January, including an FDA approval and new IgAN research.

Lipid screening after bulk orders and outreach letters increased significantly at 3 months, but supplemental text messaging had no further impact.

Targeted anti-inflammatory treatment may be reasonable for addressing the causes ofsystemic inflammation in those with severe junctional and dystrophic epidermolysis bullosa.

HCPLive spoke with Sachs about his study on palliative care for dementia, which reduced ED visits but didn’t significantly improve neuropsychiatric symptoms.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

Findings call attention to age-related neurodevelopmental differences between pediatric patients with CKD and healthy controls.

The January 2025 cardiology month in review highlights new NDA acceptances, clearance of the first Lp(a) test in molar units, and national trends in preventive aspirin use.